PE20000724A1 - 1,2,3,4-tetrahidroquinolina - Google Patents
1,2,3,4-tetrahidroquinolinaInfo
- Publication number
- PE20000724A1 PE20000724A1 PE1999000511A PE00051199A PE20000724A1 PE 20000724 A1 PE20000724 A1 PE 20000724A1 PE 1999000511 A PE1999000511 A PE 1999000511A PE 00051199 A PE00051199 A PE 00051199A PE 20000724 A1 PE20000724 A1 PE 20000724A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- halogen
- optionally substituted
- amino
- Prior art date
Links
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title abstract 4
- -1 AMINO Chemical group 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 231100000189 neurotoxic Toxicity 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE TETRAHIDROQUINOLINA I, "Y" ES C; Z ES CH UNIDO A "Y" POR UN DOBLE ENLACE; X ES CH, o Z ES METILENO, NR11; X ES C UNIDO A Y POR UN DOBLE ENLACE; A ES ALQUILENO C1-C2 OPCIONALMENTE SUSTITUIDO POR ALQUILO C1-C6 SUSTITUIDO CON OH, AMINO, ALQUILAMINO C1-C4, DIALQUILAMINO C1-C4; R ES HALOGENO, ALQUILO C1-C4; R1 ES H, HALOGENO, ALQUILO C1-C4; R2 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, H, (CH2)nR3; R3 ES COR4, NR6R5, NHCOR7, NHCOR9R8, NHSO2R10; R10 o R2 ES HETEROARILO DE 5-6 MIEMBROS; R4 ES AMINO, OH, ALCOXI C1-C4; R5 Y R6 SON H, ALQUILO C1-C4 O FORMAN JUNTOS CON N UN HETEROCICLO DE 5-7 MIEMBROS CON UN HETEROATOMO ADICIONAL; R7 ES H, ALQUILO C1-C4, ALCOXI C1-C4, FENILO; R8 ES H, ALQUILO C1-C4; R9 ES H, ALQUILO C1-C4 (OPCIONALMENTE SUSTITUIDO CON O, S, OH, CARBONILO, AMINO), FENILO; R11 ES H, ALQUILO C1-C4; R10 ES H, ALQUILO C1-C4, GRUPO PROTECTOR DE N; n ES 0-2. SON COMPUESTOS PREFERIDOS ACIDO (+/-)-CLORO-4-(2-OXO-1-FENIL-3-PIRROLIDINILIDEN)-1,2,3,4-TETRAHIDRO-2-QUINOLINCARBOXILICO; ACIDO (+/-)-7-CLORO-4-(1-FENIL-3-PIRROLIN-2-ONA-3-IL)-1,2,3,4-TETRAHIDRO-2-QUINOLINCARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DE AMINOACIDOS EXCITADORES Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DANO NEUROTOXICO, ENFERMEDADES NEURODEGENERATIVAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812408.4A GB9812408D0 (en) | 1998-06-10 | 1998-06-10 | Heterocyclic compounds |
| GBGB9812410.0A GB9812410D0 (en) | 1998-06-10 | 1998-06-10 | Heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000724A1 true PE20000724A1 (es) | 2000-08-17 |
Family
ID=26313826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000511A PE20000724A1 (es) | 1998-06-10 | 1999-06-08 | 1,2,3,4-tetrahidroquinolina |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US6362199B1 (es) |
| EP (1) | EP1086093B1 (es) |
| JP (1) | JP2002517492A (es) |
| KR (1) | KR100586762B1 (es) |
| CN (1) | CN1173970C (es) |
| AP (1) | AP2000002008A0 (es) |
| AR (1) | AR018632A1 (es) |
| AT (1) | ATE301650T1 (es) |
| AU (1) | AU753867B2 (es) |
| BG (1) | BG105123A (es) |
| BR (1) | BR9911145A (es) |
| CA (1) | CA2334727C (es) |
| CO (1) | CO5080785A1 (es) |
| CZ (1) | CZ293605B6 (es) |
| DE (1) | DE69926632T2 (es) |
| DK (1) | DK1086093T3 (es) |
| EA (1) | EA003276B1 (es) |
| EE (1) | EE200000733A (es) |
| ES (1) | ES2249010T3 (es) |
| HR (1) | HRP20000845A2 (es) |
| HU (1) | HUP0102767A3 (es) |
| ID (1) | ID27845A (es) |
| IL (2) | IL140062A0 (es) |
| IS (1) | IS5746A (es) |
| MY (1) | MY125037A (es) |
| NO (1) | NO321904B1 (es) |
| NZ (1) | NZ508638A (es) |
| OA (1) | OA11564A (es) |
| PE (1) | PE20000724A1 (es) |
| PL (1) | PL197160B1 (es) |
| TR (1) | TR200003652T2 (es) |
| TW (1) | TWI229079B (es) |
| WO (1) | WO1999064411A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY125037A (en) | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| GB9929037D0 (en) * | 1999-12-08 | 2000-02-02 | Glaxo Wellcome Spa | Heterocyclic derivatives |
| DE10000311A1 (de) | 2000-01-05 | 2001-07-12 | Gruenenthal Gmbh | Aminomethyl-Phonyl-Cyclohexanonderivate |
| DE10005302A1 (de) * | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
| DE10137488A1 (de) * | 2001-08-03 | 2003-02-20 | Gruenenthal Gmbh | Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
| DE10137487A1 (de) | 2001-08-03 | 2003-03-27 | Gruenenthal Gmbh | Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US7504508B2 (en) * | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| JP2006508077A (ja) * | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト |
| GB0327912D0 (en) * | 2003-12-02 | 2004-01-07 | Glaxo Group Ltd | Medicament |
| EP1861372A1 (en) * | 2005-02-24 | 2007-12-05 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2024516C1 (ru) * | 1989-02-02 | 1994-12-15 | Яманути Фармасьютикал Ко., Лтд. | Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли |
| US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| IL93610A0 (en) * | 1989-03-08 | 1990-12-23 | Merck Sharp & Dohme | Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them |
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| EP0854867B1 (en) | 1995-09-29 | 2002-07-31 | GLAXO WELLCOME S.p.A. | Tetrahydroquinolines as nmda antagonists |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
-
1999
- 1999-06-07 MY MYPI99002298A patent/MY125037A/en unknown
- 1999-06-08 AP APAP/P/2000/002008A patent/AP2000002008A0/en unknown
- 1999-06-08 US US09/719,188 patent/US6362199B1/en not_active Expired - Fee Related
- 1999-06-08 BR BR9911145-4A patent/BR9911145A/pt not_active Application Discontinuation
- 1999-06-08 IL IL14006299A patent/IL140062A0/xx active IP Right Grant
- 1999-06-08 AR ARP990102714A patent/AR018632A1/es active IP Right Grant
- 1999-06-08 HR HR20000845A patent/HRP20000845A2/hr not_active Application Discontinuation
- 1999-06-08 AU AU45092/99A patent/AU753867B2/en not_active Ceased
- 1999-06-08 HU HU0102767A patent/HUP0102767A3/hu unknown
- 1999-06-08 PL PL344694A patent/PL197160B1/pl not_active IP Right Cessation
- 1999-06-08 CN CNB998094145A patent/CN1173970C/zh not_active Expired - Fee Related
- 1999-06-08 DK DK99927911T patent/DK1086093T3/da active
- 1999-06-08 ES ES99927911T patent/ES2249010T3/es not_active Expired - Lifetime
- 1999-06-08 WO PCT/EP1999/003936 patent/WO1999064411A1/en not_active Ceased
- 1999-06-08 AT AT99927911T patent/ATE301650T1/de active
- 1999-06-08 CZ CZ20004587A patent/CZ293605B6/cs not_active IP Right Cessation
- 1999-06-08 EP EP99927911A patent/EP1086093B1/en not_active Expired - Lifetime
- 1999-06-08 EE EEP200000733A patent/EE200000733A/xx unknown
- 1999-06-08 CO CO99035699A patent/CO5080785A1/es unknown
- 1999-06-08 DE DE69926632T patent/DE69926632T2/de not_active Expired - Lifetime
- 1999-06-08 ID IDW20010061A patent/ID27845A/id unknown
- 1999-06-08 OA OA1200000335A patent/OA11564A/en unknown
- 1999-06-08 EA EA200001165A patent/EA003276B1/ru not_active IP Right Cessation
- 1999-06-08 TR TR2000/03652T patent/TR200003652T2/xx unknown
- 1999-06-08 JP JP2000553420A patent/JP2002517492A/ja active Pending
- 1999-06-08 PE PE1999000511A patent/PE20000724A1/es not_active Application Discontinuation
- 1999-06-08 NZ NZ508638A patent/NZ508638A/en not_active IP Right Cessation
- 1999-06-08 CA CA002334727A patent/CA2334727C/en not_active Expired - Fee Related
- 1999-06-08 KR KR1020007013994A patent/KR100586762B1/ko not_active Expired - Fee Related
- 1999-06-17 TW TW088110159A patent/TWI229079B/zh not_active IP Right Cessation
-
2000
- 2000-11-30 IS IS5746A patent/IS5746A/is unknown
- 2000-12-04 IL IL140062A patent/IL140062A/en not_active IP Right Cessation
- 2000-12-07 NO NO20006227A patent/NO321904B1/no not_active IP Right Cessation
-
2001
- 2001-01-08 BG BG105123A patent/BG105123A/xx unknown
- 2001-11-16 US US09/990,513 patent/US6413985B1/en not_active Expired - Fee Related
-
2002
- 2002-05-14 US US10/145,258 patent/US6495566B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE55098A1 (es) | Derivados de 6-fenilpiridil-2-amina | |
| PE20000724A1 (es) | 1,2,3,4-tetrahidroquinolina | |
| FI882813A0 (fi) | Pyrazolopyridinfoerening och foerfarande foer dess framstaellning. | |
| KR850001171A (ko) | 퀴놀린 화합물의 제조방법 | |
| ATE82668T1 (de) | Benzothiadiazole und ihre verwendung in verfahren und mitteln gegen pflanzenkrankheiten. | |
| ES8300112A1 (es) | Un procedimiento para preparar compuestos de cefem . | |
| ES8801245A1 (es) | Un procedimiento para preparar derivados de piperidina | |
| AR058967A2 (es) | Derivados de triazolo[4,5-d] pirimidina composiciones farmaceuticas que los contienen y proceso de preparacion para dichos compuestos | |
| ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
| BG94282A (bg) | 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они | |
| AR053109A1 (es) | DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2. | |
| SE0101579D0 (sv) | New compounds | |
| KR850006400A (ko) | 1,7-디아미노-1,4-디하이드로-4-옥소-3-(아자)퀴놀린-카복실산의 제조방법 | |
| ES8207180A1 (es) | Procedimiento de fabricacion de derivados de tetrahidro-5,67,7a 4h-tieno (3,2-c) piridinona-2 . | |
| PE20001460A1 (es) | DERIVADOS DE PIPERIDINA Y PIPERAZINA COMO INHIBIDORES DE LA FORMACION DEL PEPTIDO ß-AMILOIDE | |
| PE20030240A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
| ES2000456A6 (es) | Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas. | |
| ATE204278T1 (de) | Serotoninergische ergolin derivate | |
| ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
| PE20030345A1 (es) | 3,5-dihidroxi-2,2-dimetil-valeroamidas protegidas para la sintesis de epotilonas y derivados y un procedimiento para su preparacion | |
| AR034861A1 (es) | Un compuesto de indenoindolona, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende | |
| RU95110868A (ru) | Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция | |
| IL146916A0 (en) | Nitrobenzene and aminobenzene derivatives and a process utilizing the same | |
| GB1398687A (en) | Substituted oxazolidinones and pharmaceutical uses thereof | |
| KR950018003A (ko) | 신규한 퀴놀론 유도체 및 그의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |